Your cart is empty
Browse CatalogNovember 28, 2025
Achieving oral bioavailability for peptide therapeutics remains one of the most formidable challenges in pharmaceutical science, with the vast majority of approved peptide drugs requiring parenteral administration due to near-complete degradation and negligible absorption following oral ingestion. The gastrointestinal tract presents a multilayered barrier system evolved specifically to digest dietary proteins efficiently: the acidic gastric environment denatures folded peptide structures and activates pepsin, pancreatic serine proteases in the duodenum cleave exposed peptide bonds with broad specificity, and brush border membrane peptidases on enterocyte surfaces further degrade surviving fragments. Even intact peptides that resist enzymatic degradation face the additional hurdle of transcellular transport across the intestinal epithelium, where the hydrophilic character and high molecular weight typical of peptides severely limit passive paracellular and transcellular permeation.
Multiple formulation approaches have been developed to address the enzymatic and permeability barriers to oral peptide absorption. Enteric coatings protect peptide payloads from gastric acid and pepsin by dissolving only at the elevated pH of the small intestine, releasing the active peptide directly into the absorptive region. Co-formulation with protease inhibitors such as aprotinin, bowman-birk inhibitor, and camostat mesylate can temporarily suppress luminal proteolytic activity and improve peptide survival. Permeation enhancers including sodium N-lauroyl sarcosinate, sodium caprate, and the proprietary SNAC technology employed in oral semaglutide transiently increase paracellular and transcellular transport through modulation of tight junction integrity and membrane fluidity. The commercial success of oral semaglutide, the first oral GLP-1 receptor agonist approved for type 2 diabetes, has validated the permeation enhancer approach and reinvigorated industry investment in oral peptide delivery platforms.
Beyond conventional formulation strategies, several innovative technologies are advancing toward clinical translation for oral peptide delivery. Mucoadhesive nanoparticulate systems composed of chitosan, poly-lactic-co-glycolic acid, or lipid-based carriers can protect encapsulated peptides from degradation while promoting intimate contact with the intestinal epithelium and enhancing cellular uptake through endocytic pathways. Intestinal microneedle devices and ingestible robotic capsules represent a radically different approach, physically injecting peptide payloads through the intestinal mucosa to achieve direct access to the subepithelial vasculature with bioavailability approaching that of subcutaneous injection. On the chemical modification front, lipidation, N-methylation, and macrocyclization can collectively transform oral pharmacokinetic profiles by conferring protease resistance, enhancing membrane permeability through intramolecular hydrogen bond shielding, and promoting lymphatic absorption through association with chylomicron lipid transport pathways.